12:00 AM
 | 
Feb 07, 2005
 |  BC Week In Review  |  Company News  |  Deals

Spectrum Pharmaceuticals, Altair deal

Spectrum received exclusive worldwide rights develop and market ALTI's RenaZorb. The lanthanum-based phosphate binding compound is in preclinical development to...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >